[go: up one dir, main page]

SI1675573T2 - Sterilna injektibilna aripiprazolna formulacija z nadzorovanim sproščanjem in postopek - Google Patents

Sterilna injektibilna aripiprazolna formulacija z nadzorovanim sproščanjem in postopek

Info

Publication number
SI1675573T2
SI1675573T2 SI200430966T SI200430966T SI1675573T2 SI 1675573 T2 SI1675573 T2 SI 1675573T2 SI 200430966 T SI200430966 T SI 200430966T SI 200430966 T SI200430966 T SI 200430966T SI 1675573 T2 SI1675573 T2 SI 1675573T2
Authority
SI
Slovenia
Prior art keywords
controlled release
formulation
sterile injectable
aripiprazole
aripiprazole formulation
Prior art date
Application number
SI200430966T
Other languages
English (en)
Other versions
SI1675573T1 (sl
Inventor
Janusz W Kostanski
Takakuni Matsuda
Manoj Nerurkar
Vijay H Naringrekar
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34549292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1675573(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SI1675573T1 publication Critical patent/SI1675573T1/sl
Publication of SI1675573T2 publication Critical patent/SI1675573T2/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200430966T 2003-10-23 2004-10-18 Sterilna injektibilna aripiprazolna formulacija z nadzorovanim sproščanjem in postopek SI1675573T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51361803P 2003-10-23 2003-10-23
PCT/US2004/034367 WO2005041937A2 (en) 2003-10-23 2004-10-18 Controlled release sterile injectable aripiprazole formulation and method
EP04795514A EP1675573B2 (en) 2003-10-23 2004-10-18 Controlled release sterile injectable aripiprazole formulation and method

Publications (2)

Publication Number Publication Date
SI1675573T1 SI1675573T1 (sl) 2009-02-28
SI1675573T2 true SI1675573T2 (sl) 2012-08-31

Family

ID=34549292

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430966T SI1675573T2 (sl) 2003-10-23 2004-10-18 Sterilna injektibilna aripiprazolna formulacija z nadzorovanim sproščanjem in postopek

Country Status (32)

Country Link
US (12) US7807680B2 (sl)
EP (1) EP1675573B2 (sl)
JP (2) JP4836797B2 (sl)
KR (1) KR100931784B1 (sl)
CN (1) CN1870980B (sl)
AR (2) AR046141A1 (sl)
AT (1) ATE411797T2 (sl)
AU (1) AU2004285448C1 (sl)
BR (1) BRPI0415531B8 (sl)
CA (1) CA2543242C (sl)
CO (1) CO5690539A2 (sl)
CY (2) CY1109040T1 (sl)
DE (1) DE602004017342D1 (sl)
DK (1) DK1675573T4 (sl)
EC (2) ECSP066512A (sl)
ES (1) ES2315721T5 (sl)
FR (1) FR14C0039I1 (sl)
GE (1) GEP20115205B (sl)
IL (1) IL175072A (sl)
LU (1) LU92427I2 (sl)
MX (1) MXPA06004489A (sl)
MY (1) MY146093A (sl)
NO (2) NO334919B1 (sl)
NZ (1) NZ546063A (sl)
PE (1) PE20050811A1 (sl)
PL (1) PL1675573T4 (sl)
PT (1) PT1675573E (sl)
SI (1) SI1675573T2 (sl)
TW (2) TWI383810B (sl)
UA (1) UA82561C2 (sl)
WO (1) WO2005041937A2 (sl)
ZA (1) ZA200602347B (sl)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
AU2004285448C1 (en) 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
CN102627603A (zh) * 2004-11-18 2012-08-08 斯索恩有限公司 制备结晶阿立哌唑的方法
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ES2318693T5 (es) 2006-01-05 2018-10-04 Teva Pharmaceutical Industries Ltd Procedimiento de granulación en húmedo para la preparación de composiciones farmacéuticas de aripiprazol
ATE429906T1 (de) * 2006-01-05 2009-05-15 Teva Pharma Trockene aripiprazolformulierungen
TR200604349A2 (tr) 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
KR101892745B1 (ko) * 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
US9457026B2 (en) * 2007-07-31 2016-10-04 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
KR101125210B1 (ko) * 2009-09-11 2012-03-19 주식회사 대웅제약 아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
CN102218040A (zh) * 2010-04-13 2011-10-19 齐鲁制药有限公司 一种阿立哌唑组合物微晶的口腔崩解片及其制备方法
IL206739A (en) * 2010-06-30 2016-06-30 David Segal An injectable drug containing silitol as an active substance
CN103025318B (zh) 2010-08-24 2016-07-06 大塚制药株式会社 含有喹啉酮衍生物、和硅油和/或硅油衍生物的悬浮液和块状组合物
CN107625728A (zh) 2010-10-18 2018-01-26 大日本住友制药株式会社 注射用缓释制剂
US9757374B2 (en) * 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
CN107929239B (zh) * 2010-10-28 2021-06-01 阿尔法缇欧米茄制药咨询有限公司 阿立哌唑组合物和用于其经皮给药的方法
AR083884A1 (es) 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
CN102525915B (zh) * 2010-12-14 2016-09-28 江苏豪森药业集团有限公司 一种持续释放的注射制剂及其制备方法和用途
SG10201600202UA (en) * 2011-01-24 2016-02-26 Otsuka Pharma Co Ltd Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
IL296695B2 (en) 2011-03-18 2024-11-01 Alkermes Pharma Ireland Ltd Pharmaceutical preparations containing sorbitan esters
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102846543B (zh) * 2011-06-27 2014-11-19 上海中西制药有限公司 一种阿立哌唑药物制剂及其制备方法
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
CA2867123C (en) 2012-03-19 2021-02-16 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
PT2888593T (pt) * 2012-08-21 2018-12-12 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilizações dos mesmos
US9465041B2 (en) * 2012-08-21 2016-10-11 Janssen Pharmaceutica Nv Antibodies to paliperidone and use thereof
PT3333195T (pt) 2012-08-21 2020-10-12 Janssen Pharmaceutica Nv Anticorpos contra a quetiapina e sua utilização
CN110054693A (zh) * 2012-08-21 2019-07-26 詹森药业有限公司 喹硫平半抗原的抗体及其用途
EP2888287A4 (en) * 2012-08-21 2016-04-20 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
NZ730571A (en) 2012-09-19 2018-12-21 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
EP2838513B1 (en) * 2013-04-30 2017-04-05 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
MX376057B (es) 2014-03-20 2025-03-07 Alkermes Pharma Ireland Ltd Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion.
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
DK3508196T3 (da) * 2014-08-18 2021-08-16 Alkermes Pharma Ireland Ltd Aripiprazol-prodrugsammensætninger
ES2862098T3 (es) * 2014-08-25 2021-10-07 Alkermes Pharma Ireland Ltd Proceso de cristalización de derivados de aripiprazol en formulaciones de liberación prolongada para el tratamiento de la esquizofrenia
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
TWI584823B (zh) * 2015-08-31 2017-06-01 諾瑞特國際藥業股份有限公司 具有延長的保存期限的阿立哌唑可注射懸浮液製劑
JP6504019B2 (ja) * 2015-10-27 2019-04-24 豊田合成株式会社 発光装置
AU2016370853A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
CN105663057A (zh) * 2015-12-30 2016-06-15 中国药科大学 阿立哌唑长效混悬剂及其制备方法
AU2017303975A1 (en) * 2016-07-28 2019-03-21 Mylan Laboratories Ltd, Process for preparing sterile aripiprazole formulation
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN112545995B (zh) 2018-05-16 2024-02-23 珠海市丽珠微球科技有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
KR102486564B1 (ko) * 2019-08-23 2023-01-19 주식회사 대웅테라퓨틱스 니클로사마이드 지연방출 조성물 및 이의 항바이러스 용도
US20230049974A1 (en) * 2020-01-06 2023-02-16 Shilpa Medicare Ltd Fingolimod extended release injectable suspension
WO2021199076A1 (en) 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
HUE069157T2 (hu) * 2020-04-01 2025-02-28 Otsuka Pharma Co Ltd Eljárások aripiprazol kezelések adagoláskezdésére
KR102606504B1 (ko) * 2020-04-10 2023-11-29 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
CN115768407A (zh) * 2020-05-21 2023-03-07 江苏先声药业有限公司 一种含依匹哌唑药物组合物及其制备方法
KR102785446B1 (ko) * 2020-09-09 2025-03-25 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 항인플루엔자 바이러스용 조성물
CN112656761B (zh) * 2020-12-30 2023-09-08 河南合智医药科技有限公司 一种低刺激性阿立哌唑前药的油溶缓释注射制剂及其制备方法
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115554253B (zh) * 2022-10-14 2024-03-29 浙江圣兆药物科技股份有限公司 一种平稳释药的注射用阿立哌唑冻干制剂及其制备方法
GR1010656B (el) * 2023-03-23 2024-03-21 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει εναν ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
GR1010624B (el) * 2023-03-23 2024-01-30 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει αριπιπραζολη και μεθοδος για την παρασκευη αυτου
AU2024263986A1 (en) 2023-04-26 2025-10-09 Otsuka Pharmaceutical Co., Ltd. Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209551A (en) 1922-11-20 1924-01-17 William Mortimer Melmore Improvements in or relating to petrol and other cans
US4038389A (en) 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
CA1209477A (en) 1981-03-26 1986-08-12 Bruce E. Haeger Composition of matter comprising a lyophilized preparation of a penicillin derivative
JPS5832899A (ja) 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
US4352811A (en) 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
IL68549A (en) * 1983-05-03 1988-05-31 Kit Medidont Ltd Method and instrument for measuring moisture
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JPH03212852A (ja) 1990-01-18 1991-09-18 Hitachi Electron Eng Co Ltd 記録媒体カートリッジ搬送装置における送り機構
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
CA2044706C (en) 1990-06-15 2003-02-25 Michael Midler Jr. Crystallization method to improve crystal structure and size
IT1244880B (it) 1990-12-11 1994-09-12 Torre A Farmaceutici Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
US6193983B1 (en) 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CZ293764B6 (cs) 1993-11-19 2004-07-14 Janssen Pharmaceutica N. V. Farmaceutický prostředek s dostatečným a dlouhodobým uvolňováním léčiva, biodegradovatelné a biokompatibilní mikročástice, způsob jejich výroby a použití
JP4142095B2 (ja) 1994-06-02 2008-08-27 クアドラント・ドラツグ・デリバリー・リミテツド 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
RU2082401C1 (ru) 1994-08-18 1997-06-27 Фармацевтическое акционерное общество "Ферейн" Способ получения лекарственной формы комбинированного препарата
US6165442A (en) 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
AU729077B2 (en) 1996-08-26 2001-01-25 Transgene S.A. Cationic lipid-nucleic acid complexes
US6297231B1 (en) 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
DE69935433T2 (de) 1998-07-30 2007-10-25 Point Biomedical Corp., San Carlos Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
ATE296806T1 (de) 1999-12-09 2005-06-15 Syngenta Participations Ag Pyrazolcarboxamide und pyrazolthioamide als fungizide
JP2001187735A (ja) * 2000-01-05 2001-07-10 Towa Yakuhin Kk 安定なニコランジル含有粉末の製造法
US6559128B1 (en) 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
RU2169574C1 (ru) 2000-01-27 2001-06-27 Кобатов Алексей Иванович Способ получения биопрепарата и сухой биопрепарат
AU2001233180A1 (en) 2000-02-10 2001-08-20 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
CA2403630C (en) 2000-03-27 2009-05-26 Dale L. Boger Methods for inhibiting angiogenesis and tumor growth
US20030026844A1 (en) 2000-04-18 2003-02-06 Hee-Yong Lee Injectable sustained release pharmaceutical composition and processes for preparing the same
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002241284A (ja) * 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
MXPA03011538A (es) 2001-06-14 2004-03-09 Otsuka Pharma Co Ltd Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
EP1429734B1 (en) 2001-09-21 2007-12-26 Egalet A/S Controlled release solid dispersions of carvedilol
PE20030445A1 (es) * 2001-09-25 2003-07-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ITMI20020808A1 (it) 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
EP1551457A1 (en) * 2002-07-16 2005-07-13 Elan Pharma International Limited Liquid dosage compositions of stable nanoparticulate active agents
DE60327225D1 (de) * 2002-08-20 2009-05-28 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
AU2004285448C1 (en) * 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
JP2007509989A (ja) 2003-10-31 2007-04-19 ポイント バイオメディカル コーポレイション 超音波造影剤として有用な再構成可能なミクロスフィア組成物

Also Published As

Publication number Publication date
LU92427I2 (fr) 2014-06-11
AR046141A1 (es) 2005-11-23
NZ546063A (en) 2009-05-31
NO2014027I2 (no) 2014-10-27
JP2007509148A (ja) 2007-04-12
KR20060118450A (ko) 2006-11-23
JP2011102316A (ja) 2011-05-26
TWI421101B (zh) 2014-01-01
RU2342927C2 (ru) 2009-01-10
AR106449A2 (es) 2018-01-17
US20200061057A1 (en) 2020-02-27
RU2006109111A (ru) 2007-09-27
NO2014027I1 (no) 2014-11-10
US20210338663A1 (en) 2021-11-04
WO2005041937A2 (en) 2005-05-12
AU2004285448B2 (en) 2009-06-11
IL175072A (en) 2015-06-30
US8722679B2 (en) 2014-05-13
CY2014021I2 (el) 2017-03-15
LU92427I9 (sl) 2019-01-17
EP1675573B1 (en) 2008-10-22
TWI383810B (zh) 2013-02-01
US20080107745A1 (en) 2008-05-08
CY1109040T1 (el) 2014-07-02
EP1675573A2 (en) 2006-07-05
JP4836797B2 (ja) 2011-12-14
US20120100190A1 (en) 2012-04-26
PL1675573T4 (pl) 2016-04-29
WO2005041937A3 (en) 2006-04-06
NO334919B1 (no) 2014-07-14
US9763935B2 (en) 2017-09-19
UA82561C2 (uk) 2008-04-25
ES2315721T5 (es) 2012-08-24
PT1675573E (pt) 2008-12-30
ZA200602347B (en) 2007-09-26
ECSP066512A (es) 2006-10-10
US20170348308A1 (en) 2017-12-07
CA2543242A1 (en) 2005-05-12
CY2014021I1 (el) 2014-07-02
DK1675573T3 (da) 2009-01-05
SI1675573T1 (sl) 2009-02-28
BRPI0415531B1 (pt) 2019-07-30
CN1870980A (zh) 2006-11-29
JP5372032B2 (ja) 2013-12-18
FR14C0039I1 (fr) 2014-06-27
CA2543242C (en) 2015-04-14
US8952013B2 (en) 2015-02-10
CN1870980B (zh) 2010-06-23
TW200524638A (en) 2005-08-01
PL1675573T3 (pl) 2009-04-30
NO20062319L (no) 2006-07-21
ATE411797T2 (de) 2008-11-15
CO5690539A2 (es) 2006-10-31
BRPI0415531A (pt) 2006-12-26
US20080112985A1 (en) 2008-05-15
KR100931784B1 (ko) 2009-12-14
ES2315721T3 (es) 2009-04-01
ECSP12006512A (es) 2012-02-29
GEP20115205B (en) 2011-04-26
PL1675573T5 (pl) 2012-10-31
US20140018369A1 (en) 2014-01-16
AU2004285448C1 (en) 2021-08-19
US20080112986A1 (en) 2008-05-15
ES2315721T9 (es) 2015-11-05
MXPA06004489A (es) 2006-06-20
TW201204413A (en) 2012-02-01
US8030313B2 (en) 2011-10-04
DE602004017342D1 (de) 2008-12-04
IL175072A0 (en) 2006-08-20
EP1675573B2 (en) 2012-06-13
DK1675573T4 (da) 2012-08-06
US20050148597A1 (en) 2005-07-07
US20080221121A1 (en) 2008-09-11
US20240261280A1 (en) 2024-08-08
MY146093A (en) 2012-06-29
PE20050811A1 (es) 2005-09-25
BRPI0415531B8 (pt) 2021-05-25
US7807680B2 (en) 2010-10-05
HK1095266A1 (zh) 2007-05-04
US20150024056A1 (en) 2015-01-22
AU2004285448A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
MY146093A (en) Controlled release sterile injectable aripiprazole formulation and method
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
WO2006130607A3 (en) Controlled-release formulation useful for treating disorders associated with hepatitis c virus
EP1855721A4 (en) METHOD AND COMPOSITION FOR TREATMENT IN MAMMALS OF DISEASES AND LESIONS CAUSED BY OVEREXPRESSION OF PEROXYNITRITIS
BRPI0915142A8 (pt) Polipeptídeos, ácido nucleico e usos dos mesmos
JO2464B1 (en) Formulas contain actinacidine and binary sugars
WO2008127296A3 (en) Methods and compositions for treating tularemia
WO2005030120A3 (en) Antiangiogenic agents
WO2011075822A8 (en) Immunogenic compositions and related methods
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
MX2007011908A (es) Metodo basado en el suministro local de sustancias activas para tratar enfermedades prostaticas.
WO2007014258A3 (en) Growth hormone secretagogues
ATE467420T1 (de) Verfahren zur verwendung von guava-extrakt und zusammensetzung mit guava-extrakt
WO2006050368A3 (en) Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use
WO2001029175A3 (en) Antisense modulation of fra-1 expression
AR005619A1 (es) Procedimiento para preparar compuestos dicetonicos
WO2008147906A3 (en) Microscopic tumor injection treatment
WO2011031100A3 (en) Aripiprazole-bentonite-aea hybrid, pharmaceutical composition containing the same and method for preparing the same
WO2002040637A3 (en) Antisense modulation of pi3k p85 expression
MX2009004247A (es) Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento.
GEP20022659B (en) Process for Preparing Growth Hormone Secretagogues
ATE491469T1 (de) Zusammensetzung mit einem kolloidalen synthetischen bioresorbierbaren vektor und einem viralen vektor
WO2001013942A3 (en) Trehalose producing prokaryotic cells as vaccines
NO995020D0 (no) Plateanker, samt fremgangsmåte for styring av ankeret under dets penetrasjon ned i sjöbunnen
JP2008189643A (ja) 納豆菌注射器